CY1120570T1 - Παραγωγα 2,2-διφθοροπροπιοναμιδης της μεθυλικης βαρδοξολονης, πολυμορφα και μεθοδοι χρησης αυτων - Google Patents

Παραγωγα 2,2-διφθοροπροπιοναμιδης της μεθυλικης βαρδοξολονης, πολυμορφα και μεθοδοι χρησης αυτων

Info

Publication number
CY1120570T1
CY1120570T1 CY20181100837T CY181100837T CY1120570T1 CY 1120570 T1 CY1120570 T1 CY 1120570T1 CY 20181100837 T CY20181100837 T CY 20181100837T CY 181100837 T CY181100837 T CY 181100837T CY 1120570 T1 CY1120570 T1 CY 1120570T1
Authority
CY
Cyprus
Prior art keywords
polymorphs
methods
diffluoropropionamide
bardoxolone
methylated
Prior art date
Application number
CY20181100837T
Other languages
English (en)
Inventor
Ahmad Y. Sheikh
Alessandra MATTEI
Xiu C. Wang
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of CY1120570T1 publication Critical patent/CY1120570T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Η παρούσα εφεύρεση αφορά σε γενικές γραμμές στην ένωση: Ν-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-κυανο-2,2,6a,6b,9,9,12a-επταμεθυλο-10,14-διοξο-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a, 14,14a,14b-οκταδεκαϋδροπικενο-4a-υλο)-2,2-διφθοροπροπαναμίδη, πολύμορφα αυτής, μεθόδους για την παρασκευή και χρήση αυτής, φαρμακευτικές συνθέσεις αυτής, κιτ και είδη κατασκευής αυτής.
CY20181100837T 2013-04-24 2018-08-10 Παραγωγα 2,2-διφθοροπροπιοναμιδης της μεθυλικης βαρδοξολονης, πολυμορφα και μεθοδοι χρησης αυτων CY1120570T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361815502P 2013-04-24 2013-04-24
PCT/US2014/035279 WO2014176415A1 (en) 2013-04-24 2014-04-24 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof

Publications (1)

Publication Number Publication Date
CY1120570T1 true CY1120570T1 (el) 2019-07-10

Family

ID=50842351

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100837T CY1120570T1 (el) 2013-04-24 2018-08-10 Παραγωγα 2,2-διφθοροπροπιοναμιδης της μεθυλικης βαρδοξολονης, πολυμορφα και μεθοδοι χρησης αυτων

Country Status (36)

Country Link
US (4) US9856286B2 (el)
EP (2) EP2989114B1 (el)
JP (2) JP6409050B2 (el)
KR (2) KR102342915B1 (el)
CN (1) CN105324389B (el)
AR (1) AR096046A1 (el)
AU (2) AU2014257072C1 (el)
BR (1) BR112015027012B1 (el)
CA (1) CA2909066C (el)
CL (1) CL2015003135A1 (el)
CR (1) CR20150620A (el)
CY (1) CY1120570T1 (el)
DK (1) DK2989114T3 (el)
DO (1) DOP2015000263A (el)
EC (1) ECSP23088864A (el)
ES (1) ES2683626T3 (el)
HK (2) HK1221470A1 (el)
HR (1) HRP20181321T1 (el)
HU (1) HUE039899T2 (el)
IL (1) IL242183B (el)
LT (1) LT2989114T (el)
MX (1) MX2015014792A (el)
MY (1) MY182677A (el)
PE (1) PE20160006A1 (el)
PH (1) PH12015502459A1 (el)
PL (1) PL2989114T3 (el)
PT (1) PT2989114T (el)
RS (1) RS57571B1 (el)
RU (2) RU2693833C2 (el)
SG (2) SG10201805231WA (el)
SI (1) SI2989114T1 (el)
TW (2) TW201936625A (el)
UA (1) UA118348C2 (el)
UY (2) UY39092A (el)
WO (1) WO2014176415A1 (el)
ZA (1) ZA201507481B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356760B (es) 2008-01-11 2018-06-12 Dartmouth College Triterpenoides sinteticos y metodos de uso en el tratamiento de enfermedad.
AU2009237579C1 (en) 2008-04-18 2016-05-12 Reata Pharmaceuticals Holdings, LLC Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
CN102066397B (zh) 2008-04-18 2013-09-11 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
PE20150160A1 (es) 2012-04-27 2015-02-19 Reata Pharmaceuticals Inc Derivados de 2,2-difluoropropionamida de bardoxolona metilo, formas polimorficas y metodos de uso de los mismos
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
UY35023A (es) 2012-09-10 2014-03-31 Reata Pharmaceuticals Inc Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
TW201936625A (zh) 2013-04-24 2019-09-16 美商艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
CN106279344A (zh) * 2016-08-14 2017-01-04 吴芊葭 一种从防风中分离的天然化合物及其制备方法、医药应用
CN106309451A (zh) * 2016-08-14 2017-01-11 吴芊葭 一种头孢呋辛酯的药物组合物及其医药用途
BR112019009256A2 (pt) 2016-11-08 2019-07-16 Reata Pharmaceuticals Inc métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
CN108558985B (zh) * 2018-05-19 2019-06-07 河南省科学院高新技术研究中心 白桦脂酸衍生物及其合成方法和应用
AU2019321429B2 (en) * 2018-08-15 2022-12-08 Aiviva Biopharma, Inc. Multi-kinase inhibitors of VEGF and TGF beta and uses thereof
UA126950C2 (uk) 2018-08-20 2023-02-22 Янссен Фармацевтика Нв Інгібітори міжбілкової взаємодії keap1-nrf2
CN113966237A (zh) * 2019-03-15 2022-01-21 罗德岛大学理事会 pHLIP®介导的皮质类固醇靶向病变组织
WO2020226201A1 (ko) * 2019-05-08 2020-11-12 경상대학교병원 피부 저색소증 예방 또는 치료용 약학적 조성물, 건강기능식품 및 화장료 조성물
PE20221662A1 (es) * 2019-12-19 2022-10-26 Reata Pharmaceuticals Inc Triterpenoides sinteticos con sustituyentes a base de nitrogeno en c-17 y metodos de uso de los mismos
TW202245795A (zh) * 2021-01-18 2022-12-01 美商瑞塔醫藥有限責任公司 合成之熊果酸衍生物及其使用方法
CN113197905B (zh) * 2021-04-23 2022-04-19 浙江大学 三萜类化合物在制备神经母细胞瘤治疗药物中的应用
CN114344308A (zh) * 2021-12-22 2022-04-15 山西医科大学第二医院 甲基巴多索隆在制备防治骨关节炎的药物中的应用
US20240124393A1 (en) * 2022-09-21 2024-04-18 Sicor - Societa Italiana Corticosteroidi S.R.L. Process and intermediates for preparation of omaveloxolone and salts thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
AU2001294959A1 (en) 2000-09-29 2002-04-08 Robert M. Carlson Triterpenes having antibacterial activity
EP1322661A1 (en) 2000-09-29 2003-07-02 Regents Of The University Of Minnesota Triterpenes having fungicidal activity against yeast
US6951847B2 (en) 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
CA2430454A1 (en) 2000-11-28 2002-06-20 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
US7176237B2 (en) 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
EP1465914B1 (en) 2002-01-18 2008-12-17 Regents Of The University Of Minnesota Triterpene quaternary salts as biologically active surfactants
AU2003303128A1 (en) 2002-05-13 2004-08-13 Trustees Of Dartmouth College Inhibitors and methods of use thereof
WO2005042002A2 (en) 2003-10-30 2005-05-12 Entelos, Inc. Treatment of rhematoid arthritis with flip antagonists
US20060258752A1 (en) 2004-02-12 2006-11-16 Vander Jagt David L Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
CA2614110A1 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
WO2007112043A2 (en) 2006-03-23 2007-10-04 Advanced Life Sciences Inc. Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin
US20070249561A1 (en) 2006-04-25 2007-10-25 Taylor Bradley K Pharmacological method for treatment of neuropathic pain
WO2008016095A1 (fr) 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE
US7714012B2 (en) 2006-11-17 2010-05-11 Trustees Of Dartmouth University Synthesis and biological activities of new tricyclic-bis-enones (TBEs)
WO2008064132A2 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
WO2008111497A1 (ja) 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US20080254055A1 (en) 2007-04-11 2008-10-16 John Erich Oblong Compositions for Regulation of Hair Growth
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
WO2009023845A2 (en) 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
MX356760B (es) 2008-01-11 2018-06-12 Dartmouth College Triterpenoides sinteticos y metodos de uso en el tratamiento de enfermedad.
AU2009237579C1 (en) 2008-04-18 2016-05-12 Reata Pharmaceuticals Holdings, LLC Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
CN102066397B (zh) 2008-04-18 2013-09-11 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
WO2009129548A1 (en) 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
US7915402B2 (en) 2008-04-18 2011-03-29 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
EP2309860B1 (en) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
PL3254675T3 (pl) 2009-02-13 2019-09-30 Reata Pharmaceuticals, Inc. Kompozycje doustne o opóźnionym uwalnianiu, zawierające amorficzny cddo-me
EP3165606A1 (en) 2009-05-01 2017-05-10 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
PL2558105T3 (pl) * 2010-04-12 2020-04-30 Reata Pharmaceuticals, Inc. Metylowany bardoksolon do leczenia otyłości
WO2012009171A2 (en) 2010-07-15 2012-01-19 The Schepens Eye Research Institute, Inc. Compositions and methods of treatment of corneal endothelium disorders
EA025568B1 (ru) 2010-12-17 2017-01-30 Рита Фармасьютикалз, Инк. Пиразолильные и пиримидинильные трициклические еноны в качестве антиоксидантных модуляторов воспаления
EA026847B1 (ru) * 2011-03-11 2017-05-31 Рита Фармасьютикалз, Инк. C4-монометилтритерпеноидные производные и способы их применения
WO2012154554A1 (en) 2011-05-06 2012-11-15 Catabasis Pharmaceuticals, Inc. Fatty acid triterpene derivatives and their uses
PE20150160A1 (es) 2012-04-27 2015-02-19 Reata Pharmaceuticals Inc Derivados de 2,2-difluoropropionamida de bardoxolona metilo, formas polimorficas y metodos de uso de los mismos
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
WO2013169740A2 (en) 2012-05-08 2013-11-14 Trustees Of Dartmouth College Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
WO2014040052A2 (en) 2012-09-10 2014-03-13 Abbvie Inc. Glycyrrhetinic acid derivatives and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
DK2892911T3 (en) 2012-09-10 2017-10-23 Reata Pharmaceuticals Inc C17 heteroaryl derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
UY35023A (es) 2012-09-10 2014-03-31 Reata Pharmaceuticals Inc Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
TW201936625A (zh) 2013-04-24 2019-09-16 美商艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
EA201690456A1 (ru) 2013-08-23 2016-06-30 Рита Фармасьютикалз, Инк. Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов
WO2015112792A1 (en) 2014-01-24 2015-07-30 Abbvie Inc. Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
KR20170117092A (ko) 2015-02-12 2017-10-20 리아타 파마슈티컬즈, 아이엔씨. 항산화 염증 조절제로서의 이미다졸릴 트리사이클릭 에논
CA2998681C (en) 2015-09-23 2024-02-06 Reata Pharmaceuticals, Inc. C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
BR112019009256A2 (pt) 2016-11-08 2019-07-16 Reata Pharmaceuticals Inc métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo

Also Published As

Publication number Publication date
RU2015150069A3 (el) 2018-03-21
US11117927B2 (en) 2021-09-14
CN105324389B (zh) 2018-02-06
SI2989114T1 (sl) 2018-09-28
JP6409050B2 (ja) 2018-10-17
HK1221470A1 (zh) 2017-06-02
US11873320B2 (en) 2024-01-16
US9856286B2 (en) 2018-01-02
TW201518314A (zh) 2015-05-16
SG10201805231WA (en) 2018-08-30
CA2909066C (en) 2021-08-03
BR112015027012A2 (pt) 2017-07-25
TW201936625A (zh) 2019-09-16
KR20150144807A (ko) 2015-12-28
RU2693833C2 (ru) 2019-07-05
EP2989114A1 (en) 2016-03-02
DOP2015000263A (es) 2015-12-15
ES2683626T3 (es) 2018-09-27
DK2989114T3 (en) 2018-08-20
UY39092A (es) 2021-03-26
CN105324389A (zh) 2016-02-10
JP2019023200A (ja) 2019-02-14
CL2015003135A1 (es) 2016-06-10
SG11201508752WA (en) 2015-11-27
PT2989114T (pt) 2018-10-10
AU2014257072C1 (en) 2020-07-16
PH12015502459B1 (en) 2016-02-22
PH12015502459A1 (en) 2016-02-22
MY182677A (en) 2021-01-29
AU2014257072B2 (en) 2018-10-18
LT2989114T (lt) 2018-08-10
US20180094020A1 (en) 2018-04-05
IL242183B (en) 2019-10-31
PE20160006A1 (es) 2016-02-03
UA118348C2 (uk) 2019-01-10
UY35534A (es) 2014-10-31
HRP20181321T1 (hr) 2018-10-19
ECSP23088864A (es) 2023-12-29
US20140323579A1 (en) 2014-10-30
RU2019120236A (ru) 2019-07-22
JP2016517869A (ja) 2016-06-20
US20220073559A1 (en) 2022-03-10
KR20210018555A (ko) 2021-02-17
NZ749873A (en) 2020-09-25
AU2014257072A1 (en) 2015-10-29
HK1222179A1 (zh) 2017-06-23
HUE039899T2 (hu) 2019-02-28
EP2989114B1 (en) 2018-05-23
AR096046A1 (es) 2015-12-02
WO2014176415A1 (en) 2014-10-30
PL2989114T3 (pl) 2018-10-31
CA2909066A1 (en) 2014-10-30
CR20150620A (es) 2016-01-12
EP3453715A1 (en) 2019-03-13
RS57571B1 (sr) 2018-11-30
MX2015014792A (es) 2016-03-07
RU2015150069A (ru) 2017-05-29
RU2019120236A3 (el) 2019-12-04
TWI649330B (zh) 2019-02-01
ZA201507481B (en) 2021-05-26
BR112015027012B1 (pt) 2023-01-10
US20200062800A1 (en) 2020-02-27
AU2019200341A1 (en) 2019-02-07
KR102342915B1 (ko) 2021-12-24

Similar Documents

Publication Publication Date Title
CY1120570T1 (el) Παραγωγα 2,2-διφθοροπροπιοναμιδης της μεθυλικης βαρδοξολονης, πολυμορφα και μεθοδοι χρησης αυτων
CY1119333T1 (el) Παραγωγα 2.2-διφθοροπροπιοναμιδιου απο μεθυλικη βαρδοξολονη, πολυμορφικες μορφες και μεθοδοι χρησης αυτων
CY1121948T1 (el) Πυρρολο [1,2,f][1,2,4]tpiazineς χρησιμες για θεραπεια λοιμωξεων αναπνευστικου συγκυτιακου ιου
SV2017005487A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
TR201909788T4 (tr) C4-monometil triterpenoid türevleri ve bunların kullanım yöntemleri.
CY1126092T1 (el) Κρυσταλλικες στερεες μορφες ενος αναστολεα bet
BR112016013562A2 (pt) Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas
UY32704A (es) Compuestos de 2,3-dihidro-1h-indeno
UY35746A (es) Derivados de fenilalanina sustituidos
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
EA201590390A1 (ru) Изоксазолидиновые производные
CY1121313T1 (el) Φαρμακευτικη διεργασια και ενδιαμεσα
AR124675A2 (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
EA201691191A1 (ru) Полиморфные формы n-карбамоилметил-4(r)-фенил-2-пирролидона